BIOSPECTATOR ㅣ 2020.08.13
AutotelicBio,expands its management team to accelerate clinical trial and ASO based platform develop
Autotelic Bio announced that they had appointed two experts; MD. Yong-Kwan Jun, former director of Development Headquarters at Boryung Biopharma, and Ph. D. Chang-Hee Park, former project leader of NCE Discovery Team at Hanmi Pharm. Co., Ltd Research Center in August, 2020.
Through this appointment, Autotelic Bio will focus its capabilities on clinical trials of new anti-cancer drugs; immuno-target dual action onco-therapeutic, development of additional anti-cancer pipelines and establishment of Anti-Sense Oligonucleotide(ASO) based technology.